文献速递新药、器械与细胞基因治疗研发基础与转化研究

利用分裂内含肽与嗜肌性AAV载体实现异常糖蛋白病有效临床前基因治疗

Use of split intein and myotropic AAV vectors enables effective preclinical gene therapy for dysferlinopathy.
PubMed 文献 · Sci Transl Med · 2026-10-07

该研究针对DYSF基因突变导致的LGMDR2,利用分裂内含肽与嗜肌性AAV载体递送全长dysferlin。在LGMDR2小鼠模型中,全身给药改善了肌力、收缩力并减少病理异常,且分裂内含肽策略优于同源重组双AAV策略。

要点

  • 分裂内含肽可实现无痕重建全长dysferlin蛋白。
  • 双AAVMYO1载体全身递送在症状前和晚期均改善小鼠功能与病理。
  • 分裂内含肽效率优于同源重组双AAV策略。

核心结论

  • 分裂内含肽联合嗜肌性AAV载体的基因治疗在LGMDR2小鼠中展现出治愈潜力。

研究设计与样本

  • 在LGMDR2小鼠模型中开展临床前研究,比较分裂内含肽与同源重组双AAV策略。
  • 构建并验证了能无痕重建全长dysferlin的分裂内含肽版本。

主要发现

  • 体外实验显示重建的dysferlin可恢复dysferlin缺陷小鼠成肌细胞的膜修复缺陷。
  • 全身给予分裂内含肽与dysferlin双AAVMYO1载体,在症状前和疾病晚期均改善肌力、增加收缩力并减少组织病理异常。
  • 与同源重组双AAV策略相比,分裂内含肽技术恢复全长dysferlin效率更高,功能改善更显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Limb-girdle muscular dystrophy type R2 (LGMDR2) is a genetic disorder characterized by progressive skeletal muscle weakness and degeneration. It is caused by mutations in the DYSF gene, which prevent dysferlin expression. Dysferlin protein is essential for muscle cell membrane repair. Gene therapy using adeno-associated viral (AAV) vectors to restore full-length dysferlin expression is a promising therapeutic approach for LGMDR2. However, the large size of the dysferlin cDNA (6.2 kilobases) exceeds the ∼4.7-kilobase packaging capacity of AAV vectors, posing a challenge to effective delivery of the full-length protein. Here, we describe the use of split inteins and myotropic AAV vectors for efficient systemic gene delivery and expression of full-length dysferlin in the muscles of an LGMDR2 mouse model. We generated and validated a potent split-intein version of dysferlin that enables reconstitution of scarless full-length dysferlin protein. In vitro assessment of these constructs demonstrated a high capacity of the reconstituted dysferlin to restore membrane repair defects in dysferlinopathic mouse myoblasts. Systemic administration of split-intein and dysferlin dual AAVMYO1 vectors improved muscle strength, increased contractile force, and reduced histopathological abnormalities in the LGMDR2 mouse model at both the presymptomatic stage and late stage of the disease. Compared with the homologous recombination dual-AAV vector strategy, the split-intein technology demonstrated superior efficiency in restoring the full-length dysferlin protein and resulted in greater functional improvements. These findings demonstrate the curative potential of this split intein-based gene therapy approach for LGMDR2.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. McCormack NM, Lee-Diaz S, Reyes TR, et al. Use of split intein and myotropic AAV vectors enables effective preclinical gene therapy for dysferlinopathy. Sci Transl Med. 2026. PMID: 42842721. doi:10.1126/scitranslmed.aei5938

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。